Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Declines By 60.6%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 4,645 shares, a decline of 60.6% from the June 15th total of 11,804 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 6,542 shares, the days-to-cover ratio is presently 0.7 days.

Inhibitor Therapeutics Stock Down 3.9%

INTI traded down $0.00 during trading on Tuesday, hitting $0.08. The company’s stock had a trading volume of 184 shares, compared to its average volume of 33,584. The business’s 50 day simple moving average is $0.08 and its 200-day simple moving average is $0.08. The firm has a market cap of $13.12 million, a PE ratio of -7.55 and a beta of -0.78. Inhibitor Therapeutics has a one year low of $0.04 and a one year high of $0.12.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.